The investigators conducted a large, multicenter retrospective study of patients with breast cancer leptomeningeal metastasis (BCLM), constituting one of the largest and most comprehensively curated cohorts to date. Data from 403 patients diagnosed between November 2013 and November 2025 were collected from three major academic centers. Detailed clinical, pathological, diagnostic, and treatment data were analyzed. Overall survival (OS) was evaluated, and independent prognostic factors were identified via Cox regression. A novel Breast Cancer Leptomeningeal Graded Prognostic Assessment (BC-LGPA) model was developed and validated for risk stratification.
Study Type
OBSERVATIONAL
Enrollment
403
Patients with BCLM receive systematic therapy，IT and radiation.
Overall survival
Time from date of randomization to the date of death from any cause
Time frame: Up to approximately 30 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.